<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7005185/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Demographic, clinical and therapeutic characteristics in 107 HBV-infected patients and in 50 HBV-HCV negative controls.</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">Variable</th>
   <th colspan="1" rowspan="1" id="0-1-.">GROUP A HBsAg + on NA therapy (n = 54)</th>
   <th colspan="1" rowspan="1" id="0-2-.">GROUP B HBsAg + naive to antivirals (n = 53)</th>
   <th colspan="1" rowspan="1" id="0-3-.">GROUP C Controls (n = 50)</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>Age (years)</td>
   <td>52 (51–60)</td>
   <td>51 (48–59)</td>
   <td>50 (45–57)</td>
  </tr>
  <tr>
   <td>Male gender</td>
   <td>45 (83.33%)</td>
   <td>36 (67.92%)</td>
   <td>35 (70.0%)</td>
  </tr>
  <tr>
   <td>BMI (Kg/m 
    <sup>2</sup>) 
   </td>
   <td>25.7 (22.9–27.4)</td>
   <td>25.2 (23.3–27.3)</td>
   <td>25.4 (23.1–27.6)</td>
  </tr>
  <tr>
   <td>Creatinine (mg/dl)</td>
   <td>0.91 (0.80–1.1)</td>
   <td>0.87 (0.79–0.96)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>ALT (U/L)</td>
   <td>22 (19–35)</td>
   <td>26 (22–42)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>AST (U/L)</td>
   <td>23 (21–28)</td>
   <td>
    <i>22 (19–42)</i>
   </td>
   <td>—</td>
  </tr>
  <tr>
   <td>HBV viral load (U/L)</td>
   <td>&lt;357</td>
   <td>2,471 (478–5,848)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>HBV DNA negative</td>
   <td>22/22 (100%)</td>
   <td>0/12 (0%)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>APRI score</td>
   <td>0.32 (0.28–0.45)</td>
   <td>0.40 (0.21–0.39)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>Liver Cirrhosis</td>
   <td>1/54 (4.5%)</td>
   <td>0/54 (0%)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>Antiviral therapy duration median IQR (months)</td>
   <td>38 (20–60)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>Referred symptoms</td>
   <td/>
   <td/>
   <td>—</td>
  </tr>
  <tr>
   <td>  Asthenia</td>
   <td>5/54 (9.2%)</td>
   <td>0/12 (0%)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Body shape changes</td>
   <td>10/54 (18.5%)</td>
   <td>3/53 (5.6%)</td>
   <td>0/50 (0%)</td>
  </tr>
  <tr>
   <td>Known HBV infection duration (months)</td>
   <td>146 (42–245)</td>
   <td>152 (56–238)</td>
   <td>—</td>
  </tr>
  <tr>
   <td>Current antiviral therapy</td>
   <td/>
   <td/>
   <td>—</td>
  </tr>
  <tr>
   <td>  Lamivudine + adefovir</td>
   <td>20/54 (37.0%)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Lamivudine monotherapy</td>
   <td>2/54 (3.7%)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Tenofovir monotherapy</td>
   <td>20/54 (37%)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Entecavir monotherapy</td>
   <td>12/54 (22.2%)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>Current antiviral therapy duration (months)</td>
   <td>48 (20–60)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Entecavir</td>
   <td>24 (12–48)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Tenofovir</td>
   <td>36 (30–54)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Lamivudine + adefovir</td>
   <td>57 (16–78)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>Total antiviral therapy duration (months)</td>
   <td>60 (40–108)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Entecavir</td>
   <td>37 (24–60)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Tenofovir</td>
   <td>73 (57–108)</td>
   <td>—</td>
   <td>—</td>
  </tr>
  <tr>
   <td>  Lamivudine + adefovir</td>
   <td>96 (66–150)</td>
   <td>—</td>
   <td>—</td>
  </tr>
 </tbody>
 <tfoot>
  <p>Data are expressed as median (interquartile range). NA: Nucleoside analogues; BMI: Body Mass Index; APRI: AST-to-Platelet Ratio Index.</p>
 </tfoot>
</table>
